Pro Share Advisors LLC Aurinia Pharmaceuticals Inc. Transaction History

Pro Share Advisors LLC

  • $46.4 Billion
  • Q3 2025

A detailed history of Pro Share Advisors LLC transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 24,602 shares of AUPH stock, worth $377,640. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,602
Previous 29,199 15.74%
Holding current value
$377,640
Previous $247,000 9.72%
% of portfolio
0.0%
Previous 0.0%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 05, 2025
SELL
$7.47 - $13.14 $34,339 - $60,404
-4,597 Reduced 15.74%
24,602 $271,000
Q2 2025

Aug 07, 2025
SELL
$7.2 - $8.64 $43,610 - $52,332
-6,057 Reduced 17.18%
29,199 $247,000
Q1 2025

May 08, 2025
SELL
$7.55 - $8.77 $70,456 - $81,841
-9,332 Reduced 20.93%
35,256 $283,000
Q4 2024

Feb 13, 2025
BUY
$6.75 - $10.44 $72,704 - $112,449
10,771 Added 31.85%
44,588 $400,000
Q3 2024

Nov 13, 2024
BUY
$5.32 - $7.33 $36,442 - $50,210
6,850 Added 25.4%
33,817 $247,000
Q2 2024

Aug 13, 2024
SELL
$4.81 - $5.78 $36,060 - $43,332
-7,497 Reduced 21.75%
26,967 $153,000
Q1 2024

May 08, 2024
BUY
$4.93 - $9.31 $14,163 - $26,747
2,873 Added 9.09%
34,464 $172,000
Q4 2023

Feb 14, 2024
BUY
$7.13 - $9.49 $32,969 - $43,881
4,624 Added 17.15%
31,591 $284,000
Q3 2023

Nov 13, 2023
BUY
$7.77 - $12.27 $777 - $1,227
100 Added 0.37%
26,967 $209,000
Q2 2023

Aug 10, 2023
BUY
$8.96 - $11.69 $10,698 - $13,957
1,194 Added 4.65%
26,867 $260,000
Q1 2023

May 11, 2023
SELL
$5.94 - $11.27 $19,845 - $37,653
-3,341 Reduced 11.52%
25,673 $281,000
Q4 2022

Feb 02, 2023
BUY
$4.11 - $8.14 $9,411 - $18,640
2,290 Added 8.57%
29,014 $125,000
Q3 2022

Nov 04, 2022
BUY
$6.66 - $12.39 $4,129 - $7,681
620 Added 2.38%
26,724 $202,000
Q2 2022

Aug 01, 2022
BUY
$8.95 - $12.8 $102,423 - $146,483
11,444 Added 78.06%
26,104 $262,000
Q1 2022

May 10, 2022
SELL
$10.05 - $22.48 $36,190 - $80,950
-3,601 Reduced 19.72%
14,660 $181,000
Q4 2021

Feb 08, 2022
SELL
$17.78 - $33.08 $163,007 - $303,277
-9,168 Reduced 33.42%
18,261 $418,000
Q3 2021

Nov 12, 2021
BUY
$10.93 - $23.55 $48,113 - $103,667
4,402 Added 19.12%
27,429 $607,000
Q2 2021

Aug 13, 2021
BUY
$10.0 - $14.52 $53,940 - $78,320
5,394 Added 30.59%
23,027 $298,000
Q1 2021

May 14, 2021
SELL
$12.3 - $18.73 $23,370 - $35,587
-1,900 Reduced 9.73%
17,633 $229,000
Q4 2020

Feb 09, 2021
SELL
$12.94 - $16.05 $10,507 - $13,032
-812 Reduced 3.99%
19,533 $270,000
Q3 2020

Nov 13, 2020
BUY
$13.19 - $16.66 $30,956 - $39,101
2,347 Added 13.04%
20,345 $300,000
Q2 2020

Aug 03, 2020
BUY
$14.12 - $18.33 $45,678 - $59,297
3,235 Added 21.91%
17,998 $292,000
Q1 2020

May 15, 2020
SELL
$11.34 - $21.46 $63,889 - $120,905
-5,634 Reduced 27.62%
14,763 $214,000
Q4 2019

Feb 12, 2020
SELL
$3.88 - $21.42 $17,277 - $95,383
-4,453 Reduced 17.92%
20,397 $413,000
Q3 2019

Nov 12, 2019
SELL
$5.34 - $6.59 $10,567 - $13,041
-1,979 Reduced 7.38%
24,850 $133,000
Q2 2019

Aug 13, 2019
SELL
$6.05 - $6.75 $13,043 - $14,553
-2,156 Reduced 7.44%
26,829 $177,000
Q1 2019

May 15, 2019
BUY
$6.06 - $7.64 $375 - $473
62 Added 0.21%
28,985 $188,000
Q4 2018

Feb 14, 2019
SELL
$5.08 - $6.83 $27,508 - $36,984
-5,415 Reduced 15.77%
28,923 $197,000
Q3 2018

Nov 14, 2018
SELL
$5.27 - $6.64 $5,512 - $6,945
-1,046 Reduced 2.96%
34,338 $228,000
Q2 2018

Aug 13, 2018
SELL
$5.06 - $6.36 $17,593 - $22,113
-3,477 Reduced 8.95%
35,384 $199,000
Q1 2018

May 14, 2018
BUY
$4.85 - $5.99 $48,878 - $60,367
10,078 Added 35.01%
38,861 $202,000
Q4 2017

Feb 14, 2018
BUY
$4.53 - $7.09 $130,386 - $204,071
28,783
28,783 $130,000

Others Institutions Holding AUPH

# of Institutions
269
Shares Held
69.3M
Call Options Held
984K
Put Options Held
574K
View Full List

About Aurinia Pharmaceuticals Inc.

AUPH Quotes by TradingView
  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $2.18B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email